Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listRanolazine

Ranolazine

Synonym(s):(±)-N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-ylacetamide;(±)-4-[2-Hydroxy-3-(o-methoxyphenoxy)propyl]-1-piperazineaceto-2′,6′-xylidide

  • CAS NO.:95635-55-5
  • Empirical Formula: C24H33N3O4
  • Molecular Weight: 427.54
  • MDL number: MFCD00864690
  • EINECS: 620-450-7
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 15:53:33
Ranolazine Structural

What is Ranolazine?

Absorption

The time to reach peak serum concentration is quite variable but has been observed to be in the range of 2-6 hours, with steady-state within 3 days. The FDA indicates a Tmax of 3-5 hours. The average steady-state Cmax is about 2600 ng/mL. Absorption of ranolazine is not significantly affected by food consumption. The bioavailability of ranolazine taken in the tablet form compared to that from a solution of ranolazine is about 76%.

Toxicity

The reported LD50 of oral ranolazine in the rat is 980 mg/kg. High oral doses of ranolazine have led to dizziness, nausea, and vomiting. These effects have been shown to be dose related. High intravenous doses can cause diplopia, confusion, paresthesia, in addition to syncope. In the case of an overdose, provide supportive therapy accompanied by continuous ECG monitoring for QT interval prolongation.

Description

Ranolazine is an orally available, extended release drug for the treatment of chronic angina in patients who have failed to respond to prior angina therapy. Chronic stable angina (CSA) is a common symptom of coronary artery disease wherein plaques in the coronary vasculature restrict blood flow to the heart, which in turn leads to insufficient oxygenation of the heart, typically during physical exertion or emotional stress. A vast majority of the existing anti-anginal and anti-ischemic therapies aim to correct the imbalance between myocardial oxygen demand and supply through mechanisms that produce reductions in heart rate or blood pressure.

Chemical properties

White Solid

Originator

Roche Bioscience (US)

The Uses of Ranolazine

Ranolazine is an anti-ischemic agent which modulates myocardial metabolism. Antianginal.

The Uses of Ranolazine

antianginal, antiischemic

Indications

Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence. Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.

Background

Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.

What are the applications of Application

Ranolazine is an anti-ischemic agent which inhibits late sodium currents

Definition

ChEBI: N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide is an aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline. It is a monocarboxylic acid amide, an aromatic amide, a N-alkylpiperazine, a secondary alcohol and a monomethoxybenzene.

brand name

Ranexa (Sensus).

General Description

Ranolazine, N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide (Ranexa), is an antianginal medication thatwas approved by the Food and Drug Administration (FDA)in January 2006 for the treatment of chronic angina.Ranolazine is believed to elicit its effects by altering thetranscellular late sodium current. This, in turn, alters thesodium-dependent calcium channels during myocardial ischemia.Thus, ranolazine indirectly prevents the calciumoverload that is associated with cardiac ischemia.Ranolazine is metabolized by the cytochrome CYP3A enzymesin the liver.

Pharmacokinetics

Ranolazine exerts both antianginal and ischemic effects independent from lowering heart rate or blood pressure. It blocks IKr, the rapid portion of the delayed rectifier potassium current, and prolongs the QTc interval in a dose-dependent fashion. The Ikr is important for cardiac repolarization. Ranolazine exerts its therapeutic effects without negative chronotropic, dromotropic, or inotropic actions neither at rest, nor during exercise.

Clinical Use

Add on therapy for angina

Synthesis

Two syntheses, one from the inventors at Roche and other from a group in Hungary, of Ranolazine have been described in the patent literature. The original synthesis is highlighted in the Scheme. Reaction of 2,6-dimethylaniline 46 with chloroacetyl chloride (47) in the presence of triethylamine for 4h at 0oC gave amide 48 in 82% yield. This chloro amide 48 was reacted with piperazine in refluxing ethanol for 2 h to give piperazinyl amide 50. Reaction of amide 50 with epoxide intermediate 53, prepared by reacting 2-methoxy phenol 51 with epichlorohydrin, in refluxing isopropanol for 3 h followed by treatment with HCl/methanol gave ranolazine dihydrochloride (VII) in 73% yield.

Synthesis_95635-55-5

Drug interactions

Potentially hazardous interactions with other drugs
Anti-arrhythmics: avoid with disopyramide.
Antibacterials: concentration possibly increased by clarithromycin and telithromycin - avoid concomitant use; concentration reduced by rifampicin - avoid.
Antifungals: concentration increased by ketoconazole and possibly itraconazole, posaconazole and voriconazole - avoid.
Antivirals: concentration possibly increased by atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir and tipranavir - avoid.
Beta-blockers: avoid with sotalol.
Ciclosporin: concentration of both drugs possibly increased.
Grapefruit juice: concentration of ranolazine possibly increased - avoid.
Statins: concentration of simvastatin increased - maximum dose of simvastatin is 20 mg.
Tacrolimus: concentration of tacrolimus increased.

Metabolism

Ranolazine is rapidly heavily metabolized in the liver an gastrointestinal tract through the activity of the CYP3A4 enzyme with minor contributions from CYP2D6. More than 40 ranolazine metabolites have been found in plasma and more than 100 metabolites have been identified in the urine.
Ranolazine and some of its metabolites are known to weakly inhibit CYP3A4. However, the activity of the metabolites of ranolazine has not been fully elucidated.

Metabolism

Extensively metabolised in the gastrointestinal tract and liver. Four main metabolites have been identified.
Approximately 75% of a dose is excreted in the urine with the remainder in the faeces.

Properties of Ranolazine

Melting point: 119-1200C
Boiling point: 624.1±55.0 °C(Predicted)
Density  1.174±0.06 g/cm3(Predicted)
storage temp.  Sealed in dry,Room Temperature
solubility  DMSO (Slightly), Methanol (Slightly)
form  Solid
pka 14.06±0.20(Predicted)
color  White
CAS DataBase Reference 95635-55-5(CAS DataBase Reference)

Safety information for Ranolazine

Computed Descriptors for Ranolazine

Ranolazine manufacturer

Lupin Ltd

1Y
Phone:+91-8019896181
Whatsapp: +91 8019896181
product: 95635-55-5 99%
Inquiry

Apotex Pharmachem India Pvt Ltd

1Y
Phone:+91-8022891000
product: 95635-55-5 Ranolazine 98%
Inquiry

Aurobindo Pharma Limited

1Y
Phone:+91-4066725000
product: Ranolazine 98%
Inquiry

Glenmark Pharmaceuticals Limited

1Y
Phone:+912240189999
product: Ranolazine 95635-55-5 98%
Inquiry

Hetero Drugs Limited

1Y
Phone:+914023704923
product: 95635-55-5 Ranolazine 98%
Inquiry

Mankind Pharma Limited

1Y
Phone:+91-1146541111
product: 95635-55-5 98%
Inquiry

Aarti Industries Limited (AIL)

1Y
Phone:+91-9920899935
Whatsapp: +91 9920899935
product: Ranolazine 98%
Inquiry

Vivimed Labs Ltd

1Y
Phone:+91-4066086608
product: Ranolazine 95635-55-5 98%
Inquiry

Unichem Laboratories Ltd

1Y
Phone:+91-2266888333
product: 95635-55-5 Ranolazine 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.